{"id":355165,"date":"2026-11-19T14:19:28","date_gmt":"2026-11-19T08:49:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355165"},"modified":"2026-11-19T14:19:28","modified_gmt":"2026-11-19T08:49:28","slug":"alpa-laboratories-analyst-review-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/","title":{"rendered":"Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Alpa Laboratories Stock Snapshot (18 Nov 2026 close)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b951.59<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b992.50 \/ \u20b946.10<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b9109 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 51.6 vs 40.1<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b932.22 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> Loss of \u20b91.85 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Alpa Laboratories analyst review 2027<\/strong> finds no brokerage coverage as of November 2026. Q2 FY27 sales rose about 10% to \u20b932.22 crore, but EBITDA turned negative at minus \u20b90.99 crore and the company posted a net loss of \u20b91.85 crore, against a small profit a year ago. FY26 revenue was \u20b9121.6 crore with profit of \u20b915 crore. The stock closed at \u20b951.59, about 44% below its 52-week high, and trades at about 0.58 times book value, so the <strong>Alpa Laboratories share price target 2027<\/strong> question depends on a return to operating profit.<\/p>\n<\/div>\n<p>The <strong>Alpa Laboratories analyst review 2027<\/strong> covers an Indore-based maker of finished medicines such as injections, tablets, capsules and ointments, sold under its own brand, through contract manufacturing and in export markets. Readers searching for an <strong>Alpa Laboratories share price target 2027<\/strong> will not find a named <strong>brokerage<\/strong> figure, so results and <strong>book value<\/strong> guide this review.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/alpa\/alpa-laboratories-ltd-share-price-today\">Alpa Laboratories<\/a> closed at \u20b951.59 on 18 November 2026, about 44% below its 52-week high of \u20b992.50 and about 12% above its low of \u20b946.10. This Alpa Laboratories analyst review 2027 covers the September quarter and the <strong>Alpa Laboratories stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=alpa-laboratories-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#What_Analysts_Say_in_the_Alpa_Laboratories_Analyst_Review_2027\" title=\"What Analysts Say in the Alpa Laboratories Analyst Review 2027\">What Analysts Say in the Alpa Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Q2_FY27_Results_in_the_Alpa_Laboratories_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Alpa Laboratories Analyst Review 2027\">Q2 FY27 Results in the Alpa Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#How_Alpa_Laboratories_Makes_Money\" title=\"How Alpa Laboratories Makes Money\">How Alpa Laboratories Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Growth_Triggers_in_the_Alpa_Laboratories_Analyst_Review_2027\" title=\"Growth Triggers in the Alpa Laboratories Analyst Review 2027\">Growth Triggers in the Alpa Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Key_Risks_in_the_Alpa_Laboratories_Analyst_Review_2027\" title=\"Key Risks in the Alpa Laboratories Analyst Review 2027\">Key Risks in the Alpa Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Alpa_Laboratories_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Alpa Laboratories Analyst Review 2027: Stock at a Glance\">Alpa Laboratories Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#What_to_Watch_After_the_Alpa_Laboratories_Analyst_Review_2027\" title=\"What to Watch After the Alpa Laboratories Analyst Review 2027\">What to Watch After the Alpa Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Final_Word_on_the_Alpa_Laboratories_Analyst_Review_2027\" title=\"Final Word on the Alpa Laboratories Analyst Review 2027\">Final Word on the Alpa Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#What_does_the_Alpa_Laboratories_analyst_review_2027_show\" title=\"What does the Alpa Laboratories analyst review 2027 show?\">What does the Alpa Laboratories analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Is_there_an_Alpa_Laboratories_share_price_target_2027_from_brokerages\" title=\"Is there an Alpa Laboratories share price target 2027 from brokerages?\">Is there an Alpa Laboratories share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#What_does_Alpa_Laboratories_make\" title=\"What does Alpa Laboratories make?\">What does Alpa Laboratories make?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Why_did_Alpa_Laboratories_post_a_loss_in_Q2_FY27\" title=\"Why did Alpa Laboratories post a loss in Q2 FY27?\">Why did Alpa Laboratories post a loss in Q2 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#Is_Alpa_Laboratories_stock_undervalued_based_on_the_Alpa_Laboratories_analyst_review_2027\" title=\"Is Alpa Laboratories stock undervalued based on the Alpa Laboratories analyst review 2027?\">Is Alpa Laboratories stock undervalued based on the Alpa Laboratories analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#What_risks_does_the_Alpa_Laboratories_analyst_review_2027_highlight\" title=\"What risks does the Alpa Laboratories analyst review 2027 highlight?\">What risks does the Alpa Laboratories analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alpa-laboratories-analyst-review-2\/#What_should_investors_track_after_the_Alpa_Laboratories_analyst_review_2027\" title=\"What should investors track after the Alpa Laboratories analyst review 2027?\">What should investors track after the Alpa Laboratories analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Say_in_the_Alpa_Laboratories_Analyst_Review_2027\"><\/span><strong>What Analysts Say in the Alpa Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>No verified coverage<\/td>\n<td>Not available<\/td>\n<td>Not available<\/td>\n<td>As of November 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>No <strong>brokerage<\/strong> covers Alpa Laboratories, and institutions hold less than 0.5% of the company. With a market value of about \u20b9109 crore, it sits outside research coverage.<\/p>\n<p><strong>Book value<\/strong> is the clearest reference point. <strong>Book value<\/strong> per share is about \u20b988.36, well above the share price, so the market values the company at about 0.58 times net worth. This Alpa Laboratories analyst review 2027 explains why that discount has widened.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Alpa_Laboratories_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Alpa Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue<\/th>\n<th>EBITDA<\/th>\n<th>Net Profit<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Sep 2026 (Q2 FY27)<\/td>\n<td>\u20b932.22 crore<\/td>\n<td>Minus \u20b90.99 crore<\/td>\n<td>Loss of \u20b91.85 crore<\/td>\n<\/tr>\n<tr>\n<td>Jun 2026 (Q1 FY27)<\/td>\n<td>\u20b929.70 crore<\/td>\n<td>\u20b91.81 crore<\/td>\n<td>\u20b90.98 crore<\/td>\n<\/tr>\n<tr>\n<td>Mar 2026 (Q4 FY26)<\/td>\n<td>\u20b931.24 crore<\/td>\n<td>\u20b93.44 crore<\/td>\n<td>\u20b91.38 crore<\/td>\n<\/tr>\n<tr>\n<td>Dec 2025 (Q3 FY26)<\/td>\n<td>\u20b929.96 crore<\/td>\n<td>\u20b92.42 crore<\/td>\n<td>\u20b91.59 crore<\/td>\n<\/tr>\n<tr>\n<td>Sep 2025 (Q2 FY26)<\/td>\n<td>\u20b929.32 crore<\/td>\n<td>\u20b90.82 crore<\/td>\n<td>\u20b90.11 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Revenue rose about 10% from a year ago and about 8% from the June quarter, but <strong>EBITDA<\/strong> turned negative at minus \u20b90.99 crore. The company posted a <strong>net profit<\/strong> loss of \u20b91.85 crore, its weakest quarter in the table.<\/p>\n<p>Higher sales with an operating loss points to cost pressure, such as raw materials, staff or new capacity costs. For this Alpa Laboratories analyst review 2027, the December quarter will show whether this was a one-off.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Alpa_Laboratories_Makes_Money\"><\/span><strong>How Alpa Laboratories Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alpa makes finished dosage forms at its plant near Indore.<\/p>\n<ul>\n<li><strong>Own brand:<\/strong> generic, over-the-counter and veterinary medicines sold under the Alpa name.<\/li>\n<li><strong>Contract manufacturing:<\/strong> production for other pharma companies.<\/li>\n<li><strong>Injections and liquids:<\/strong> liquid and dry powder injections, among other forms.<\/li>\n<li><strong>Exports:<\/strong> sales to markets in Africa, Asia and Latin America.<\/li>\n<\/ul>\n<p>FY26 revenue was about \u20b9121.6 crore with profit of about \u20b915 crore, against \u20b9135.8 crore and \u20b919.5 crore in FY25. Operating cash flow was about \u20b99.3 crore in FY26. Those numbers frame this Alpa Laboratories analyst review 2027.<\/p>\n<p>Annual profit has been much higher than recent quarters suggest. The four quarters from December 2025 to September 2026 add up to only about \u20b92.1 crore of profit, compared with \u20b915 crore for FY26 as a whole. That points to a large contribution from one earlier quarter or from non-operating income, so the core business currently earns far less than the annual figure implies.<\/p>\n<p>Small formulation makers face pricing pressure from larger rivals, and contract manufacturing margins depend on how fully the plant is used. Export orders can also be lumpy, so revenue and margins can move sharply between quarters.<\/p>\n<p>The company has been carrying out a capital spending programme to add capacity. New capacity often adds costs before it adds revenue, so margins could stay under pressure until the expansion starts contributing to sales.<\/p>\n<p>The balance sheet is almost debt-free, with <strong>debt to equity<\/strong> of about 0.01, so the losses do not create immediate financial strain. The issue is return on equity, which has fallen to about 1.1%, the main reason the stock trades well below book.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Alpa_Laboratories_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Alpa Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Sales growth:<\/strong> <strong>Q2 FY27<\/strong> revenue up about 10%.<\/li>\n<li><strong>Debt-free:<\/strong> <strong>debt to equity<\/strong> near zero.<\/li>\n<li><strong>Capacity additions:<\/strong> new capacity could lift volumes over time.<\/li>\n<li><strong>Export reach:<\/strong> sales across several emerging markets.<\/li>\n<li><strong>Discount to book:<\/strong> about 0.58 times book feeds the Alpa Laboratories share price target 2027 debate.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Alpa_Laboratories_Analyst_Review_2027\"><\/span><strong>Key Risks in the Alpa Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Operating loss:<\/strong> <strong>EBITDA<\/strong> turned negative in <strong>Q2 FY27<\/strong>.<\/li>\n<li><strong>Weak core earnings:<\/strong> about \u20b92.1 crore profit over four quarters.<\/li>\n<li><strong>Low returns:<\/strong> return on equity of about 1.1%.<\/li>\n<li><strong>Pricing pressure:<\/strong> competition from larger drug makers.<\/li>\n<li><strong>Share price fall:<\/strong> about 44% below its high, a caution in the Alpa Laboratories analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Alpa Laboratories With Other Pharma Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alpa_Laboratories_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Alpa Laboratories Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (18 Nov 2026 close)<\/td>\n<td>\u20b951.59<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b992.50 \/ \u20b946.10<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b9109 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM)<\/td>\n<td>51.6<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>0.58<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>\u20b988.36<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>1.1%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.01<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>\u20b91.00<\/td>\n<\/tr>\n<tr>\n<td>FY26 Revenue \/ Net Profit<\/td>\n<td>\u20b9121.6 crore \/ \u20b915.0 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>P\/E<\/strong> of about 52 looks high only because trailing earnings have fallen sharply. Price to <strong>book value<\/strong> of 0.58 is the more useful measure. In this Alpa Laboratories analyst review 2027, returns need to recover before the discount can narrow.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>57.29%<\/td>\n<td>57.19%<\/td>\n<td>Down 0.10 points<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>0.35%<\/td>\n<td>0.35%<\/td>\n<td>No change<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>0.00%<\/td>\n<td>0.07%<\/td>\n<td>Up 0.07 points<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>42.35%<\/td>\n<td>42.39%<\/td>\n<td>Flat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>promoter<\/strong> group holds about 57.2%, led by managing director Paresh Chawla at 34.3% and Shitul Shah at 10.2%. Stable holdings are a neutral point in the Alpa Laboratories analyst review 2027.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Alpa_Laboratories_Analyst_Review_2027\"><\/span><strong>What to Watch After the Alpa Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>December quarter:<\/strong> a return to positive <strong>EBITDA<\/strong>.<\/li>\n<li><strong>Margins:<\/strong> recovery towards earlier levels.<\/li>\n<li><strong>Capacity:<\/strong> progress on the capital spending plan.<\/li>\n<li><strong>Exports and contracts:<\/strong> new orders that lift plant use.<\/li>\n<li><strong>Coverage:<\/strong> any research note would give an Alpa Laboratories share price target 2027 reference.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Alpa_Laboratories_Analyst_Review_2027\"><\/span><strong>Final Word on the Alpa Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Alpa Laboratories analyst review 2027<\/strong> shows a debt-free drug maker with growing sales but an operating loss in <strong>Q2 FY27<\/strong> and weak core earnings. The stock trades near its 52-week low and well below <strong>book value<\/strong>.<\/p>\n<p>The <strong>Alpa Laboratories stock outlook 2027<\/strong> depends on restoring margins and lifting returns. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Alpa_Laboratories_analyst_review_2027_show\"><\/span><strong>What does the Alpa Laboratories analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows higher sales but a loss. Q2 FY27 revenue rose about 10% to \u20b932.22 crore, but the company posted a net loss of \u20b91.85 crore. EBITDA was minus \u20b90.99 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_there_an_Alpa_Laboratories_share_price_target_2027_from_brokerages\"><\/span><strong>Is there an Alpa Laboratories share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>No brokerage covers Alpa Laboratories as of November 2026. The stock closed at \u20b951.59 on 18 November 2026. Book value per share is about \u20b988.36.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Alpa_Laboratories_make\"><\/span><strong>What does Alpa Laboratories make?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Alpa makes finished medicines such as injections, tablets, capsules and ointments at its Indore plant. It sells under its own brand, does contract manufacturing and exports. FY26 revenue was about \u20b9121.6 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Alpa_Laboratories_post_a_loss_in_Q2_FY27\"><\/span><strong>Why did Alpa Laboratories post a loss in Q2 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating costs rose faster than sales, turning EBITDA negative at minus \u20b90.99 crore. Revenue still grew about 10%. The four quarters to September 2026 earned only about \u20b92.1 crore in total.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alpa_Laboratories_stock_undervalued_based_on_the_Alpa_Laboratories_analyst_review_2027\"><\/span><strong>Is Alpa Laboratories stock undervalued based on the Alpa Laboratories analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock trades at about 0.58 times book value. Return on equity has fallen to about 1.1%. The P\/E of about 52 reflects depressed earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Alpa_Laboratories_analyst_review_2027_highlight\"><\/span><strong>What risks does the Alpa Laboratories analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are the operating loss, weak core earnings and pricing pressure. The stock is about 44% below its 52-week high of \u20b992.50. Returns are very low.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Alpa_Laboratories_analyst_review_2027\"><\/span><strong>What should investors track after the Alpa Laboratories analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track whether EBITDA turns positive in the December quarter. Watch margins, progress on new capacity and new export or contract orders. Return on equity also matters.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Alpa Laboratories analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows higher sales but a loss. Q2 FY27 revenue rose about 10% to \u20b932.22 crore, but the company posted a net loss of \u20b91.85 crore. EBITDA was minus \u20b90.99 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is there an Alpa Laboratories share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No brokerage covers Alpa Laboratories as of November 2026. The stock closed at \u20b951.59 on 18 November 2026. Book value per share is about \u20b988.36.\"}},{\"@type\":\"Question\",\"name\":\"What does Alpa Laboratories make?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alpa makes finished medicines such as injections, tablets, capsules and ointments at its Indore plant. It sells under its own brand, does contract manufacturing and exports. FY26 revenue was about \u20b9121.6 crore.\"}},{\"@type\":\"Question\",\"name\":\"Why did Alpa Laboratories post a loss in Q2 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Operating costs rose faster than sales, turning EBITDA negative at minus \u20b90.99 crore. Revenue still grew about 10%. The four quarters to September 2026 earned only about \u20b92.1 crore in total.\"}},{\"@type\":\"Question\",\"name\":\"Is Alpa Laboratories stock undervalued based on the Alpa Laboratories analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock trades at about 0.58 times book value. Return on equity has fallen to about 1.1%. The P\/E of about 52 reflects depressed earnings.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Alpa Laboratories analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are the operating loss, weak core earnings and pricing pressure. The stock is about 44% below its 52-week high of \u20b992.50. Returns are very low.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Alpa Laboratories analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track whether EBITDA turns positive in the December quarter. Watch margins, progress on new capacity and new export or contract orders. Return on equity also matters.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alpa Laboratories grew Q2 FY27 sales about 10% to \u20b932.22 crore but posted a loss of \u20b91.85 crore as operating profit turned negative. The Indore drug maker trades at about 0.58 times book, near its 52-week low. With no brokerage coverage, we review results and risks.<\/p>\n","protected":false},"author":38,"featured_media":355164,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,26213,4341,6686],"class_list":["post-355165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-alpa-laboratories","tag-analyst-review","tag-pharmaceuticals"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355164"],"rank_math_title":["Alpa Laboratories Share Price Target 2027: Review"],"rank_math_description":["Alpa Laboratories analyst review 2027: Q2 FY27 sales up 10% to \u20b932.22 crore but a \u20b91.85 crore loss, Indore drug maker at 0.58x book, near 52-week low, risks."],"rank_math_focus_keyword":["Alpa Laboratories analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/alpa-laboratories-analyst-review-2027-sales-rise-10-but-q2-swings-to-a-loss-1.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355165"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355165\/revisions"}],"predecessor-version":[{"id":355166,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355165\/revisions\/355166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355164"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}